Streetbeat News

Products Services

JAGX

Jaguar Health has announced that it has been granted a new patent in Japan. The patent is for the company's proprietary drug, Mytesi, which is used for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Portfolio Pulse from Bill Haddad

September 13, 2023 | 12:33 pm

IINN

Inspira has announced the 510(k) FDA submission of INSPIRA ART100, with management estimating FDA clearance within approximately 6 months.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 12:32 pm

AAPL

Apple Inc. has launched the iPhone 15 series with several design and hardware upgrades. However, many of these features, such as the USB-C port, Action button, Spatial Video, and more, were already present on Android phones. The iPhone 15 Pro Max's periscope camera and titanium frame are also not new to the smartphone industry.

Portfolio Pulse from Rounak Jain

September 13, 2023 | 12:31 pm

MYNZ

Mainz Biomed announced positive topline results from its ColoFuture study, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 12:30 pm

HOTH

Hoth Therapeutics announced that its new molecular entity, HT-KIT, has been successful in killing cancer cells in gastrointestinal stromal tumors and acute myeloid leukemia. This has led to an increase in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 12:28 pm

EIGR

Eiger BioPharmaceuticals has decided to discontinue its Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 12:24 pm

BR

Broadridge Financial Solutions Inc has launched its next-gen digital communications platform, the Broadridge Communications Cloud. The platform aims to enhance service delivery by providing investors with improved customer experiences and data-centric insights while reducing costs. It can manage various essential communications such as confirmations, statements, corporate actions, proxies and prospectuses.

Portfolio Pulse from Shivani Kumaresan

September 13, 2023 | 12:22 pm

HOTH

Hoth Therapeutics has announced that its new molecular entity, HT-KIT, has shown promising results in preclinical studies for systemic mastocytosis. The drug has demonstrated the ability to kill cancer cells in both gastrointestinal stromal tumors and acute myeloid leukemia.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 12:20 pm

LCTX

Lineage Cell Therapeutics announced that additional results from the RG6501 Phase 1/2A trial will be presented at the 23rd EURETINA Congress in Amsterdam, October 5-8, 2023. The presentation will be given by Adiel Barak, M.D., on behalf of Roche and Genentech.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 12:19 pm

OCGN

Ocugen has announced an update from its Phase 1/2 trial of OCU400, with 83% of subjects showing stabilization or improvement in the treated eye. The study also demonstrated a 'favorable safety and tolerability profile'.

Portfolio Pulse from Bill Haddad

September 13, 2023 | 12:17 pm